The name of the most successful #prescription drug to be launched in 2022 should come as no surprise to anyone who reads People Magazine. 💫 Dozens of celebrities – Oprah Winfrey, Amy Schumer, Whoopi Goldberg, Charles Barkley, Rosie O’Donnell, Elon Musk, and many others – have admitted to using #Mounjaro or its GLP-1 agonist cousin #Ozempic to help control their weight, pushing the brands from the pharmacy to the tabloids and helping Mounjaro earn more than $5 billion in sales in its first full year on the market, good enough for second in Eli Lilly’s entire portfolio. For pharma’s launch class of 2022, it would seem, weight loss is the new black. Read more of Joshua Slatko's analysis in "First year after launch: an extra-pharma phenomenom." https://lnkd.in/eqWEMUZp #MedAdNews
Med Ad News’ Post
More Relevant Posts
-
Way back in 1849, Charles Pfizer and Charles Erhart laid the foundation of not just the company we know today as Pfizer, but also the future that opens up the 3-dimensional progress based on the vision ,goal and motto that soars ahead of time zone , that shines the same in all time zone(s) -past ,present, future that is #breakthroughsthatchangepatientslives. 2024, marks the year where #Pfizer for 175 years have had an extra ordinary impact on global health, it all sums up to: “Outdo Yesterday,” and to bring the next generation of breakthroughs to patients--for the next 175 years and beyond. #pfizer175 PS: “Talent wins games, but teamwork and intelligence win championships.” this mere concept has been intellectualized and internalized a bit more naturally after conversing with this inspirational lady Maira Akhtar thanks a bunch, it's always a privilege to be in a same frame 😇 #pfizerfamily
To view or add a comment, sign in
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> BIO's new CEO takes a patriotic pivot to win back Congress, pushing industry to rethink China relationship >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #productmarketing
To view or add a comment, sign in
-
We’re excited to welcome Arvind Balasundaram from Regeneron Pharmaceuticals Inc., Suzanne Taylor from Microsoft, Michael Kaye from Archer, and Kevin Wong from The Trevor Project to the Fireside Chat "Harmonizing Humanity and Tech: The Modern Marketing Mix" at our upcoming Intrigue MAdTech Summit in New York on October 24th! Join us as these industry leaders explore how to balance human creativity with technological innovation, shaping the future of marketing. Stay tuned for more updates! #IntrigueMAdTech #INTNY #DigitalMarketing #TechAndHumanity #NYCEvent #MarketingLeadership
To view or add a comment, sign in
-
We’re excited to welcome Arvind Balasundaram from Regeneron Pharmaceuticals Inc., Suzanne Taylor from Microsoft, Michael Kaye from Archer, and Kevin Wong from The Trevor Project to the Fireside Chat "Harmonizing Humanity and Tech: The Modern Marketing Mix" at our upcoming Intrigue MAdTech Summit in New York on October 24th! Join us as these industry leaders explore how to balance human creativity with technological innovation, shaping the future of marketing. Stay tuned for more updates! #IntrigueMAdTech #INTNY #DigitalMarketing #TechAndHumanity #NYCEvent #MarketingLeadership
To view or add a comment, sign in
-
20 Years+ International Learning & Development Expert I Business Consultant I Edutech & Digital Education Advocate I Sustainability in Education in UAE Award 🥇
Integrative Leadership " Case study "- River Blindness & Merck CEO : Back in the 1970s, River Blindness was among the most feared diseases in the world, and scientists had long been frustrated in their efforts to stop the spread of the disease in developing nations. Then, researchers at Merck discovered a potential cure for river blindness. The drug would cost over $200 million to create, and it would only be available to those who could afford it. When Merck's CEO (Roy Vagelos) was unable to get the governments of developing countries to agree to the drug's development, it became clear that the drug would never be profitable for Merck, but Vagelos chose to distribute it free to the people whose lives it would save. Many within the company argued that this was a costly error that violated the CEO's fiduciary duty to the company's stockholders. Vagelos, however, believed that this decision was in line with Merck's guiding mission of preserving and improving human life. This humanitarian decision helped to almost completely eliminate River Blindness. It also helped Merck's reputation and attracted some of the world's best medical minds. #business #Coaching #enterprenuership #leadershipmastery #leadership #sararamadan #businesscasestudy #integrativeleadership #leadershipinorganization
To view or add a comment, sign in
-
CEO at Salesgasm | Driving Growth Through 10 Years, 40 Summits, and 15,000+ Delegates | Collaboration Catalyst with 1,450+ Industry Leaders/Speakers
We’re excited to welcome Arvind Balasundaram from Regeneron Pharmaceuticals Inc., Suzanne Taylor from Microsoft, Michael Kaye from Archer, and Kevin Wong from The Trevor Project to the Fireside Chat "Harmonizing Humanity and Tech: The Modern Marketing Mix" at our upcoming Intrigue MAdTech Summit in New York on October 24th! Join us as these industry leaders explore how to balance human creativity with technological innovation, shaping the future of marketing. Stay tuned for more updates! #IntrigueMAdTech #INTNY #DigitalMarketing #TechAndHumanity #NYCEvent #MarketingLeadership
To view or add a comment, sign in
-
Quest lab data can help provide valuable insights to R&D teams to develop your target product profile, which will translate throughout your drug development program. Invest early to ensure your team is on the right path. https://lnkd.in/gjJ8AdH4
To view or add a comment, sign in
-
9 Rare Diseases | Healthcare Analytics | Oncology | Speaker | Product Launch | Biomarkers | Strategy
Drug development carries inherent risks. Interested in de-risking your investments? Leveraging laboratory data for insights is crucial, as up to 70% of clinical decisions rely on laboratory test results. If you're keen to learn more, feel free to reach out. #DrugDevelopment #Investments #LabData #Insights
Quest lab data can help provide valuable insights to R&D teams to develop your target product profile, which will translate throughout your drug development program. Invest early to ensure your team is on the right path. https://lnkd.in/gjJ8AdH4
To view or add a comment, sign in
-
It's about to get real in the weight-loss med arena! 🏋️♂️💊 Eli Lilly and Novo Nordisk are ramping up supply, which could leave smaller players like Hims & Hers scrambling to differentiate themselves. The stage is set for a showdown, and here's how I see it playing out: 1. **Market Dominance**: Let's be honest, when pharmaceutical giants step up their game, it's usually game over for the little guys. Eli Lilly and Novo Nordisk have the resources to flood the market, leaving compounded versions looking like the underdog. 2. **Consumer Choices**: With more readily available options from trusted brands, consumers are likely going to lean towards these well-established names. Why go for a knock-off when you can have the original? 3. **Regulatory Hurdles**: Smaller companies focusing on compounded drugs will likely face increased scrutiny. As big players dominate, regulatory bodies might tighten the noose on compounded versions, making it even tougher for companies like Hims & Hers. 4. **Innovation vs. Imitation**: This market shift could either stifle innovation or ignite a new wave of creativity. Will smaller firms rise to the challenge, or fade into obscurity? Only time will tell! 5. **Consumer Education**: It's going to be crucial for companies to educate their customers on the differences, if any. Transparency will be key in retaining trust and driving sales. The big players are jazzing up their act, and it’s time for everyone else to either step up or step aside. Buckle up, it's going to be one wild ride in the world of weight-loss meds! 🔥 The question of the day: Can the little fish survive in a pond filled with sharks? 🦈 https://lnkd.in/emdgfXDV
To view or add a comment, sign in
-
It’s coming folks, if you want to wait and see what happens, “feel it out”, that’s fine..but change is coming, and it’s change for the better. Your employees are paying attention now. If you are ready to start building benefit plans that are about best drug for best price possible today..let’s go! Mark Cuban Cost Plus Drug Company, PBC #transparency SmithRx
Watch CNBC's full interview with billionaire investor Mark Cuban
cnbc.com
To view or add a comment, sign in
4,013 followers